Ignite Creation Date:
2024-05-05 @ 7:06 PM
Last Modification Date:
2024-10-26 @ 9:43 AM
Study NCT ID:
NCT00603668
Status:
COMPLETED
Last Update Posted:
2021-08-16
First Post:
2008-01-08
Brief Title:
Phase III Study of Different Doses and Dose Schedules of Milatuzumab hLL1 in CLL
Sponsor:
Gilead Sciences
Organization:
Gilead Sciences
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-08
Start Date Type:
None
Primary Completion Date:
2013-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-02
Completion Date Type:
ACTUAL
First Submit Date:
2008-01-08
First Submit QC Date:
January 16 2008
Study First Post Date:
2008-01-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
2021-08-12
Disp First Submit QC Date:
August 12 2021
Disp First Post Date:
2021-08-16
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2021-08-12
Last Update Post Date:
2021-08-16
Last Update Post Date Type:
ACTUAL